Eton Ebitda vs Net Interest Income Analysis

ETON Stock

USD 11.23 0.48 4.47%

Eton Pharmaceuticals financial indicator trend analysis is much more than just examining Eton Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eton Pharmaceuticals is a good investment. Please check the relationship between Eton Pharmaceuticals Ebitda and its Net Interest Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.

Ebitda vs Net Interest Income

Ebitda vs Net Interest Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eton Pharmaceuticals Ebitda account and Net Interest Income. At this time, the significance of the direction appears to have weak relationship.

The correlation between Eton Pharmaceuticals' Ebitda and Net Interest Income is 0.3. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Net Interest Income in the same time period over historical financial statements of Eton Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eton Pharmaceuticals' Ebitda and Net Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Eton Pharmaceuticals are associated (or correlated) with its Net Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Interest Income has no effect on the direction of Ebitda i.e., Eton Pharmaceuticals' Ebitda and Net Interest Income go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Ebitda

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most indicators from Eton Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eton Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.At this time, Eton Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 25th of November 2024, Enterprise Value is likely to grow to about 71.5 M, while Selling General Administrative is likely to drop about 12.9 M.

	2023	2024 (projected)
Depreciation And Amortization	901K	783.6K
Interest Income	323.2K	244.8K

Depreciation And Amortization Interest Income

Eton Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock
Total Assets		0.68	0.73	0.64	0.89	0.31	-0.31	-0.9	0.93	0.82	0.81	-0.32	0.16	0.82	0.94	0.44	0.42	0.94	0.58	0.93	0.84	0.95	0.5	0.98	0.52	0.94
Other Current Liab	0.68		0.99	0.04	0.42	-0.09	-0.15	-0.75	0.57	0.47	0.73	-0.64	-0.23	0.47	0.65	0.59	-0.09	0.63	0.1	0.66	0.76	0.54	0.23	0.61	-0.19	0.66
Total Current Liabilities	0.73	0.99		0.1	0.47	-0.08	-0.16	-0.79	0.64	0.52	0.75	-0.66	-0.17	0.52	0.7	0.61	-0.04	0.68	0.19	0.71	0.79	0.59	0.24	0.67	-0.11	0.7
Total Stockholder Equity	0.64	0.04	0.1		0.75	0.3	-0.71	-0.29	0.51	0.81	0.19	0.18	0.16	0.81	0.44	-0.32	0.17	0.43	0.32	0.4	0.16	0.62	0.31	0.74	0.87	0.43
Net Tangible Assets	0.89	0.42	0.47	0.75		0.62	-0.38	-0.79	0.8	0.81	0.61	0.09	0.3	0.81	0.84	0.13	0.54	0.84	0.6	0.83	0.62	0.97	0.72	0.91	0.75	0.86
Property Plant And Equipment Net	0.31	-0.09	-0.08	0.3	0.62		-0.05	-0.35	0.31	0.34	0.13	0.71	0.65	0.34	0.42	-0.15	0.64	0.43	0.41	0.4	0.23	0.55	0.94	0.34	0.54	0.43
Net Debt	-0.31	-0.15	-0.16	-0.71	-0.38	-0.05		-0.04	-0.17	-0.77	0.2	-0.13	-0.07	-0.77	-0.02	0.6	0.4	0.0	0.33	0.01	0.15	-0.2	-0.13	-0.45	-0.5	-0.02
Retained Earnings	-0.9	-0.75	-0.79	-0.29	-0.79	-0.35	-0.04		-0.9	-0.56	-0.91	0.4	-0.17	-0.56	-0.97	-0.69	-0.57	-0.96	-0.65	-0.98	-0.94	-0.91	-0.54	-0.83	-0.29	-0.98
Accounts Payable	0.93	0.57	0.64	0.51	0.8	0.31	-0.17	-0.9		0.73	0.76	-0.37	0.41	0.73	0.91	0.55	0.6	0.91	0.68	0.92	0.85	0.88	0.45	0.91	0.53	0.92
Cash	0.82	0.47	0.52	0.81	0.81	0.34	-0.77	-0.56	0.73		0.38	-0.05	0.31	1.0	0.63	-0.08	0.14	0.62	0.21	0.61	0.47	0.74	0.49	0.89	0.67	0.63
Non Current Assets Total	0.81	0.73	0.75	0.19	0.61	0.13	0.2	-0.91	0.76	0.38		-0.55	-0.12	0.38	0.91	0.79	0.48	0.91	0.53	0.92	0.94	0.78	0.32	0.69	0.06	0.9
Non Currrent Assets Other	-0.32	-0.64	-0.66	0.18	0.09	0.71	-0.13	0.4	-0.37	-0.05	-0.55		0.43	-0.05	-0.29	-0.7	0.17	-0.28	-0.04	-0.33	-0.49	-0.09	0.51	-0.23	0.39	-0.29
Other Assets	0.16	-0.23	-0.17	0.16	0.3	0.65	-0.07	-0.17	0.41	0.31	-0.12	0.43		0.31	0.21	-0.04	0.58	0.21	0.42	0.21	0.15	0.26	0.56	0.24	0.51	0.22
Cash And Short Term Investments	0.82	0.47	0.52	0.81	0.81	0.34	-0.77	-0.56	0.73	1.0	0.38	-0.05	0.31		0.63	-0.08	0.14	0.62	0.21	0.61	0.47	0.74	0.49	0.89	0.67	0.63
Common Stock Total Equity	0.94	0.65	0.7	0.44	0.84	0.42	-0.02	-0.97	0.91	0.63	0.91	-0.29	0.21	0.63		0.62	0.62	1.0	0.68	0.99	0.94	0.95	0.59	0.88	0.39	0.99
Common Stock Shares Outstanding	0.44	0.59	0.61	-0.32	0.13	-0.15	0.6	-0.69	0.55	-0.08	0.79	-0.7	-0.04	-0.08	0.62		0.41	0.62	0.52	0.64	0.81	0.37	0.01	0.3	-0.32	0.61
Non Current Liabilities Total	0.42	-0.09	-0.04	0.17	0.54	0.64	0.4	-0.57	0.6	0.14	0.48	0.17	0.58	0.14	0.62	0.41		0.63	0.79	0.63	0.51	0.61	0.54	0.37	0.49	0.63
Capital Surpluse	0.94	0.63	0.68	0.43	0.84	0.43	0.0	-0.96	0.91	0.62	0.91	-0.28	0.21	0.62	1.0	0.62	0.63		0.69	0.99	0.94	0.95	0.59	0.87	0.4	0.99
Other Current Assets	0.58	0.1	0.19	0.32	0.6	0.41	0.33	-0.65	0.68	0.21	0.53	-0.04	0.42	0.21	0.68	0.52	0.79	0.69		0.69	0.58	0.68	0.41	0.56	0.52	0.7
Other Stockholder Equity	0.93	0.66	0.71	0.4	0.83	0.4	0.01	-0.98	0.92	0.61	0.92	-0.33	0.21	0.61	0.99	0.64	0.63	0.99	0.69		0.94	0.95	0.57	0.87	0.38	1.0
Total Liab	0.84	0.76	0.79	0.16	0.62	0.23	0.15	-0.94	0.85	0.47	0.94	-0.49	0.15	0.47	0.94	0.81	0.51	0.94	0.58	0.94		0.79	0.45	0.74	0.09	0.92
Net Invested Capital	0.95	0.54	0.59	0.62	0.97	0.55	-0.2	-0.91	0.88	0.74	0.78	-0.09	0.26	0.74	0.95	0.37	0.61	0.95	0.68	0.95	0.79		0.68	0.93	0.62	0.96
Property Plant And Equipment Gross	0.5	0.23	0.24	0.31	0.72	0.94	-0.13	-0.54	0.45	0.49	0.32	0.51	0.56	0.49	0.59	0.01	0.54	0.59	0.41	0.57	0.45	0.68		0.52	0.45	0.6
Total Current Assets	0.98	0.61	0.67	0.74	0.91	0.34	-0.45	-0.83	0.91	0.89	0.69	-0.23	0.24	0.89	0.88	0.3	0.37	0.87	0.56	0.87	0.74	0.93	0.52		0.63	0.88
Net Working Capital	0.52	-0.19	-0.11	0.87	0.75	0.54	-0.5	-0.29	0.53	0.67	0.06	0.39	0.51	0.67	0.39	-0.32	0.49	0.4	0.52	0.38	0.09	0.62	0.45	0.63		0.42
Common Stock	0.94	0.66	0.7	0.43	0.86	0.43	-0.02	-0.98	0.92	0.63	0.9	-0.29	0.22	0.63	0.99	0.61	0.63	0.99	0.7	1.0	0.92	0.96	0.6	0.88	0.42

Click cells to compare fundamentals

Eton Pharmaceuticals Account Relationship Matchups

Eton Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	17.1M	26.3M	27.5M	25.0M	31.7M	26.6M
Other Current Liab	1.4M	1.2M	1.4M	3.7M	9.0M	9.5M
Total Current Liabilities	2.0M	3.8M	4.6M	6.5M	16.2M	17.1M
Total Stockholder Equity	10.6M	15.7M	17.6M	13.1M	15.5M	12.7M
Net Tangible Assets	9.8M	15.1M	14.0M	8.3M	9.6M	12.2M
Property Plant And Equipment Net	1.3M	1.0M	219K	260K	150K	142.5K
Net Debt	(7.5M)	(14.2M)	(7.7M)	(9.8M)	(16.0M)	(16.8M)
Retained Earnings	(64.2M)	(92.2M)	(94.1M)	(103.1M)	(104.1M)	(109.3M)
Accounts Payable	575K	2.3M	1.8M	1.8M	1.8M	1.6M
Cash	12.1M	21.3M	14.4M	16.3M	21.4M	19.7M
Non Current Assets Total	2.1M	1.6M	3.9M	5.0M	4.9M	2.9M
Non Currrent Assets Other	61K	40K	21K	12K	10.8K	10.3K
Other Assets	61K	232K	21K	12K	10.8K	10.3K
Long Term Debt	4.5M	6.8M	5.3M	5.4M	6.2M	4.0M
Cash And Short Term Investments	12.1M	21.3M	14.4M	16.3M	21.4M	19.7M
Retained Earnings Total Equity	(45.9M)	(64.2M)	(92.2M)	(103.1M)	(92.8M)	(97.5M)
Common Stock Shares Outstanding	17.8M	21.0M	25.2M	25.1M	25.6M	21.6M
Liabilities And Stockholders Equity	17.1M	26.3M	27.5M	25.0M	31.7M	26.6M
Non Current Liabilities Total	4.6M	6.9M	5.3M	5.5M	22K	20.9K
Capital Surpluse	72.2M	74.7M	107.8M	116.2M	133.6M	82.0M
Inventory	380K	1.2M	550K	557K	911K	572K
Other Current Assets	2.1M	4.2M	6.4M	1.3M	1.1M	1.1M
Other Stockholder Equity	74.7M	107.8M	111.7M	116.2M	119.5M	97.9M
Total Liab	6.5M	10.7M	9.8M	12.0M	16.3M	9.2M
Net Invested Capital	15.1M	22.7M	24.3M	19.5M	20.9M	19.2M
Property Plant And Equipment Gross	1.3M	1.0M	219K	260K	545K	479.5K
Total Current Assets	15.0M	24.7M	23.6M	20.0M	26.8M	23.7M
Net Working Capital	13.0M	20.9M	19.0M	13.5M	10.6M	13.2M
Short Term Debt	133K	280K	1.4M	1.0M	5.4M	5.6M
Intangible Assets	725K	575K	3.6M	4.8M	4.7M	5.0M
Property Plant Equipment	1.3M	1.0M	219K	72K	64.8K	61.6K

Pair Trading with Eton Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Eton Stock

0.94	GMAB	Genmab AS	Pair Corr
0.93	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.89	VALN	Valneva SE ADR	Pair Corr
0.87	LEGN	Legend Biotech Corp	Pair Corr
0.85	ME	23Andme Holding	Pair Corr

The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.

The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Eton Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eton Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eton Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eton Pharmaceuticals Stock:

How To Invest In Eton

Details

Is Eton Stock a good investment?

Details

What is Eton Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.

You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.13)

Earnings Share

(0.26)

Revenue Per Share

1.219

Quarterly Revenue Growth

(0.24)

Return On Assets

(0.12)

The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eton Ebitda vs Net Interest Income Analysis

Ebitda vs Net Interest Income

Ebitda vs Net Interest Income Correlation Analysis

Correlation Coefficient

Ebitda

Net Interest Income

Eton Pharmaceuticals fundamental ratios Correlations

Eton Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eton Pharmaceuticals fundamental ratios Accounts

Pair Trading with Eton Pharmaceuticals

Moving against Eton Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Capital Surpluse	+ 1.0	Common Stock Total Equity
Common Stock	+ 1.0	Other Stockholder Equity
Total Current Liabilities	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Common Stock Total Equity
Common Stock	+ 0.99	Common Stock Total Equity

Common Stock	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Capital Surpluse	- 0.96	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Net Invested Capital	- 0.91	Retained Earnings